MedTrace Logo

A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy Adults

NCT07444294 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2026-03-02

No results posted yet for this study

Summary

A phase 1 study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of SRK-439 in healthy adults

Conditions

  • Healthy

Interventions

DRUG

Placebo

Matching placebo to SRK-439, subcutaneous administration

DRUG

SRK-439

Single ascending dose, subcutaneous administration

DRUG

SRK-439

Multiple ascending dose, subcutaneous administration

Sponsors & Collaborators

  • Scholar Rock, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-21
Primary Completion
2026-12-17
Completion
2027-06-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07444294 on ClinicalTrials.gov